West Pharmaceutical Services, Inc. (WST) News
Track canonical SquawkNews coverage tagged to WST, West Pharmaceutical Services, Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 13 indexed stories across 7 publication days and is ordered by the same first-publication timeline used by LiveCast.
H
Westinghouse Submits Draft IPO Registration
Westinghouse files draft IPO registration statement
EQUITY | Jul 31, 2026, 11:23 AM UTC
L
CASY EA EW ESS HON WST session lows
CASY EA EW ESS HON WST session lows
EQUITY | Jul 24, 2026, 04:09 PM UTC
H
West Pharmaceutical CEO Highlights GLP-1 And Biologics Momentum
West Pharmaceutical Services, Inc. (NYSE: WST ) reported better than expected second quarter 2026 earnings. The injectable solutions company reported adjusted earnings of $2.37 per share, beating the consensus of $2.08.
EARNINGS | Jul 23, 2026, 03:32 PM UTC
H
Full Transcript: West Pharmaceutical Servs Q2 2026 Earnings Call
West Pharmaceutical Servs (NYSE: WST ) reported second-quarter financial results on Thursday. The transcript from the company's second-quarter earnings call has been provided below. APIs provide real-time access to earni
EARNINGS | Jul 23, 2026, 01:22 PM UTC
H
WST West Pharmaceutical RESULTS: Q2, Q2 net sales $872.3M vs. EST $838.6M, Q2 EPS $2.15, West Pharmaceutical Earnings Notes:, - West Pharmac
WST West Pharmaceutical RESULTS: Q2, Q2 net sales $872.3M vs. EST $838.6M, Q2 EPS $2.15, West Pharmaceutical Earnings Notes:, - West Pharmaceutical Q2 ADJ EPS $2.37 vs. EST $2.08, Outlook FY net sales $3,345-3.380B vs. E
RATES | Jul 23, 2026, 10:25 AM UTC
L
West Pharmaceutical ups FY26 adjusted EPS view to $9.85-$9.05 from $8.40-$8.75
Consensus $8.62. Raises...
EARNINGS | Jul 23, 2026, 10:14 AM UTC
L
West Pharmaceutical reports Q2 adjusted EPS $2.37, consensus $2.08
Reports Q2 revenue...
EARNINGS | Jul 23, 2026, 10:09 AM UTC
H
West Pharmaceutical Servs Raises FY2026 GAAP EPS Guidance from $8.15-$8.50 to $8.85-$9.05 vs $8.41 Est
West Pharmaceutical Servs (NYSE: WST ) raises FY2026 GAAP EPS guidance from $8.15-$8.50 to $8.85-$9.05 vs $8.41 analyst estimate..
EARNINGS | Jul 23, 2026, 10:08 AM UTC
L
WST - West Pharmaceutical Services Enters Into Multiple Amended Distribution And Crosslicensing Agreements With Daikyo Seiko
WST - West Pharmaceutical Services Enters Into Multiple Amended Distribution And Crosslicensing Agreements With Daikyo Seiko
EQUITY | Jul 14, 2026, 08:47 PM UTC
L
WST West Pharmaceutical Services - Co and daikyo seiko enter amended crosslicense and distributorship agreements effective July 14, 2026 - S
WST West Pharmaceutical Services - Co and daikyo seiko enter amended crosslicense and distributorship agreements effective July 14, 2026 - SEC filing West Pharmaceutical Services Inc: Co maintains a 49% ownership interes
REGULATION | Jul 14, 2026, 08:32 PM UTC
H
West Pharmaceutical price target raised to $365 from $325 at Morgan Stanley
Morgan Stanley raised the firm's price target on West Pharmaceutical to $365 from $325 and keeps an Equal Weight rating on the shares. The firm is updating its model ahead of the earnings report.
EARNINGS | Jul 09, 2026, 11:01 AM UTC
L
Evercore ISI Adjusts Price Target on West Pharmaceutical Services to $410 From $390
() -- West Pharmaceutical Services (WST) has an average rating of overweight and mean price target of $367.15, according to analysts polled by FactSet. ( covers equity, commodity and economic research from major banks an
EQUITY | Jul 06, 2026, 01:10 PM UTC
L
Keybanc Maintains Overweight on West Pharmaceutical Servs, Raises Price Target to $390
Keybanc analyst Paul Knight maintains West Pharmaceutical Servs (NYSE: WST ) with a Overweight and raises the price target from $350 to $390.
EQUITY | Jul 02, 2026, 01:02 PM UTC